UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                  SCHEDULE 13G



             INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
          TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
                            PURSUANT TO RULE 13d-2(b)

                                (Amendment No. 2)



                               Antares Pharma Inc.
--------------------------------------------------------------------------------
                                (Name of Issuer)


                     Common Stock, par value $0.01 per share
--------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                    036642106
--------------------------------------------------------------------------------
                                 (CUSIP Number)


                                December 31, 2007
--------------------------------------------------------------------------------
             (Date of Event Which Requires Filing of this Statement)


     Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

          [_] Rule 13d-1(b)

          [X] Rule 13d-1(c)

          [_] Rule 13d-1(d)



CUSIP No.  036642106
---------------------


1.   NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

          Philip Korn

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
                                                                       (a) [_]
                                                                       (b) [X]

3.   SEC USE ONLY



4.   CITIZENSHIP OR PLACE OF ORGANIZATION

          United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.   SOLE VOTING POWER

          300,033

6.   SHARED VOTING POWER

          642,796

7.   SOLE DISPOSITIVE POWER

          300,033

8.   SHARED DISPOSITIVE POWER

          2,173,200

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          2,473,233

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES
     CERTAIN SHARES                                                        [_]

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

          3.8%

12.  TYPE OF REPORTING PERSON

          IN

--------------------------------------------------------------------------------



CUSIP No.  036642106
---------------------


Item 1(a).  Name of Issuer:

                 Antares Pharma, Inc.
            --------------------------------------------------------------------

Item 1(b).  Address of Issuer's Principal Executive Offices:

                 250 Phillips Blvd., Suite 290
                 Ewing, New Jersey 08618
            --------------------------------------------------------------------


Item 2(a).  Name of Persons Filing:

                 Philip Korn
            --------------------------------------------------------------------

Item 2(b).  Address of Principal Business Office, or if None, Residence:

                 Philip Korn
                 c/o Weiss Multi-Strategy Advisers LLC
                 One State Street, 20th Floor
                 Hartford, CT 06103
            -------------------------------------------------------------------

Item 2(c).  Citizenship:

                 United States
            --------------------------------------------------------------------

Item 2(d).  Title of Class of Securities:

                 Common Stock, par value $0.01 per share
            --------------------------------------------------------------------

Item 2(e).  CUSIP Number:

                 036642106
            --------------------------------------------------------------------


Item 3.     If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b)
            or (c), Check Whether the Person Filing is a:

      (a) [_]    Broker or dealer registered under Section 15 of the Exchange
                 Act.

      (b) [_]    Bank as defined in Section 3(a)(6) of the Exchange Act.

      (c) [_]    Insurance company as defined in Section 3(a)(19) of the
                 Exchange Act.

      (d) [_]    Investment company registered under Section 8 of the
                 Investment Company Act.

      (e) [_]    An investment adviser in accordance with Rule
                 13d-1(b)(1)(ii)(E);

      (f) [_]    An employee benefit plan or endowment fund in accordance with
                 Rule 13d-1(b)(1)(ii)(F);

      (g) [_]    A parent holding company or control person in accordance with
                 Rule 13d-1(b)(1)(ii)(G);

      (h) [_]    A savings association as defined in Section 3(b) of the
                 Federal Deposit Insurance Act;

      (i) [_]    A church plan that is excluded from the definition of an
                 investment company under Section 3(c)(14) of the Investment
                 Company Act;

      (j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).


Item 4.     Ownership.

                 Provide the following information regarding the aggregate
            number and percentage of the class of securities of the issuer
            identified in Item 1.

      (a)   Amount beneficially owned:

                 Philip Korn:  2,473,233 shares
            --------------------------------------------------------------------

      (b)   Percent of class:

                 Philip Korn:  3.8%
            --------------------------------------------------------------------

      (c)   Number of shares as to which Philip Korn has:

         (i)     Sole power to vote or to direct the vote
                                                                       300,033
                                                                   ------------,

         (ii)    Shared power to vote or to direct the vote
                                                                       642,796
                                                                   ------------,

         (iii)   Sole power to dispose or to direct the
                 disposition of                                        300,033
                                                                   ------------,

         (iv)    Shared power to dispose or to direct the
                 disposition of                                      2,173,200
                                                                   ------------.

Item 5.     Ownership of Five Percent or Less of a Class.

                 If this statement is being filed to report the fact that as of
            the date hereof the Reporting Person has ceased to be the beneficial
            owner of more than five percent of the class of securities check the
            following [X].
            --------------------------------------------------------------------


Item 6.     Ownership of More Than Five Percent on Behalf of Another Person.

                 If any other person is known to have the right to receive or
            the power to direct the receipt of dividends from, or the proceeds
            from the sale of, such securities, a statement to that effect should
            be included in response to this item and, if such interest relates
            to more than five percent of the class, such person should be
            identified. A listing of the shareholders of an investment company
            registered under the Investment Company Act of 1940 or the
            beneficiaries of employee benefit plan, pension fund or endowment
            fund is not required.

                 N/A
            --------------------------------------------------------------------


Item 7.     Identification and Classification of the Subsidiary Which Acquired
            the Security Being Reported on by the Parent Holding Company or
            Control Person.

                 If a parent holding company or Control person has filed this
            schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under
            Item 3(g) and attach an exhibit stating the identity and the Item 3
            classification of the relevant subsidiary. If a parent holding
            company or control person has filed this schedule pursuant to Rule
            13d-1(c) or Rule 13d-1(d), attach an exhibit stating the
            identification of the relevant subsidiary.

                 N/A
            --------------------------------------------------------------------


Item 8.     Identification  and  Classification  of Members of the Group.

                 If a group has filed this schedule pursuant to
            ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an
            exhibit stating the identity and Item 3 classification of each
            member of the group. If a group has filed this schedule pursuant to
            ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the
            identity of each member of the group.

                 N/A
            --------------------------------------------------------------------


Item 9.     Notice of Dissolution of Group.

                 Notice of dissolution of a group may be furnished as an
            exhibit stating the date of the dissolution and that all further
            filings with respect to transactions in the security reported on
            will be filed, if required, by members of the group, in their
            individual capacity. See Item 5.

                 N/A
            --------------------------------------------------------------------

Item 10.    Certifications.

                 Certification for Rule 13d-1(c): By signing below each
            Reporting Person certifies that, to the best of its knowledge and
            belief, the securities referred to above were not acquired and are
            not held for the purpose of or with the effect of changing or
            influencing the control of the issuer of the securities and were not
            acquired and are not held in connection with or as a participant in
            any transaction having that purpose or effect.





                                    SIGNATURE


     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


                                        February 13, 2008
                                        ---------------------------
                                        (Date)


                                        /s/ Philip Korn (1)
                                        ---------------------------
                                            Philip Korn



(1)   The Reporting Person disclaims beneficial ownership except to the extent
      of his pecuniary interest therein.





SK 25405 0003 852025